George Siber Purchases 25,000 Shares of Genocea Biosciences Inc (GNCA) Stock

Genocea Biosciences Inc (NASDAQ:GNCA) Director George Siber purchased 25,000 shares of the firm’s stock in a transaction on Friday, August 31st. The shares were acquired at an average price of $0.61 per share, with a total value of $15,250.00. Following the completion of the acquisition, the director now owns 27,017 shares in the company, valued at approximately $16,480.37. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

George Siber also recently made the following trade(s):

  • On Thursday, September 6th, George Siber purchased 25,000 shares of Genocea Biosciences stock. The shares were acquired at an average price of $0.61 per share, with a total value of $15,250.00.
  • On Tuesday, September 4th, George Siber purchased 25,000 shares of Genocea Biosciences stock. The shares were acquired at an average price of $0.62 per share, with a total value of $15,500.00.
  • On Wednesday, August 29th, George Siber purchased 25,000 shares of Genocea Biosciences stock. The shares were acquired at an average price of $0.61 per share, with a total value of $15,250.00.

Shares of GNCA opened at $0.82 on Thursday. The company has a debt-to-equity ratio of 0.95, a current ratio of 6.84 and a quick ratio of 6.84. The stock has a market capitalization of $62.13 million, a PE ratio of -0.41 and a beta of 1.03. Genocea Biosciences Inc has a one year low of $0.49 and a one year high of $2.15.

Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. sell-side analysts forecast that Genocea Biosciences Inc will post -0.47 earnings per share for the current fiscal year.

GNCA has been the subject of a number of recent analyst reports. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Zacks Investment Research downgraded Genocea Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, July 11th. Finally, HC Wainwright set a $5.00 price target on Genocea Biosciences and gave the stock a “buy” rating in a report on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $3.79.

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new stake in shares of Genocea Biosciences in the 4th quarter valued at about $145,000. California State Teachers Retirement System grew its stake in shares of Genocea Biosciences by 166.6% in the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 78,469 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in shares of Genocea Biosciences in the 1st quarter valued at about $177,000. LMR Partners LLP acquired a new stake in shares of Genocea Biosciences in the 2nd quarter valued at about $175,000. Finally, GSA Capital Partners LLP grew its stake in shares of Genocea Biosciences by 266.9% in the 1st quarter. GSA Capital Partners LLP now owns 234,065 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 170,265 shares during the period. Institutional investors own 60.23% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Article: Investing in Growth Stocks

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply